Literature DB >> 25704022

3,3'-Diindolylmethane increases bone mass by suppressing osteoclastic bone resorption in mice.

Tai-Yong Yu1, Wei-Jun Pang2, Gong-She Yang2.   

Abstract

3,3'-Diindolylmethane (DIM), a major acid-condensation product or metabolite of indole-3-carbinol which is found in cruciferous vegetables, has been shown to have anticancer, anti-inflammatory, and multiple immune stimulating effects. However, its function in bone metabolism is poorly understood. This study evaluated the effect of DIM on bone mass in mice under physiological and pathological conditions. Eight-week-old female mice received injections of a vehicle or 0.1mg/g of DIM, twice a week for four weeks. We found that DIM treatment significantly increased bone mass as assessed by dual-energy X-ray absorptiometry (DEXA) and micro-computed tomography (μCT). Further, Bone histomorphometric analyses showed that this treatment significantly reduced bone resorption parameters, but did not increase bone formation parameters. Furthermore, we use ovariectomized (OVX)-induced osteoporotic mouse model, and explore function of DIM in skeletal pathological processes. Bone phenotype analyses revealed that the administration of DIM in this study effectively prevented OVX-induced bone loss resulting from increased bone resorption. Our results demonstrated that DIM increased bone mass by suppressing osteoclastic bone resorption in bone metabolism under both physiological and pathological conditions. Accordingly, DIM may be of value in the treatment and the possible prevention of bone diseases characterized by bone loss, such as postmenopausal osteoporosis.
Copyright © 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3,3′-Diindolylmethane (DIM); Bone metabolism; Bone resorption; Osteoporosis; Ovariectomized (OVX)

Mesh:

Substances:

Year:  2014        PMID: 25704022     DOI: 10.1016/j.jphs.2014.11.006

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  4 in total

Review 1.  Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches.

Authors:  Vivek Kumar Sharma; Thakur Gurjeet Singh; Nirbhay Kumar Prabhakar; Ashi Mannan
Journal:  Neurochem Res       Date:  2022-02-08       Impact factor: 3.996

2.  Tetrandrine enhances the ubiquitination and degradation of Syk through an AhR-c-src-c-Cbl pathway and consequently inhibits osteoclastogenesis and bone destruction in arthritis.

Authors:  Yugai Jia; Yu Tao; Changjun Lv; Yufeng Xia; Zhifeng Wei; Yue Dai
Journal:  Cell Death Dis       Date:  2019-01-15       Impact factor: 8.469

Review 3.  IDO and Kynurenine Metabolites in Peripheral and CNS Disorders.

Authors:  Yi-Shu Huang; Joy Ogbechi; Felix I Clanchy; Richard O Williams; Trevor W Stone
Journal:  Front Immunol       Date:  2020-03-05       Impact factor: 7.561

4.  Kynurenine Promotes RANKL-Induced Osteoclastogenesis In Vitro by Activating the Aryl Hydrocarbon Receptor Pathway.

Authors:  Nada H Eisa; Sakamuri V Reddy; Ahmed M Elmansi; Galina Kondrikova; Dmitry Kondrikov; Xing-Ming Shi; Chad M Novince; Mark W Hamrick; Meghan E McGee-Lawrence; Carlos M Isales; Sadanand Fulzele; William D Hill
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.